论文部分内容阅读
对慢性阻塞性肺病（ＣＯＰＤ）患者外周血单个核细胞（ＰＢＭＣｓ）表面的ＣＤ１１ａ／ＣＤ１８，ＣＤ１１ｂ／ＣＤ１８（ＡＰＡＡＰ法）及ＣＤ４４（流式细胞分析法）粘附分子表达及血浆中可溶性Ｅ．Ｐ－选择素水平进行检测。结果：ＣＯＰＤ急性加重期患者ＰＢＭＣｓ表面ＣＤ１１ａ、ＣＤ１１ｂ及ＣＤ４４分子表达明显增高，血浆中可溶性Ｅ．Ｐ－选择素水平亦显著增高，与正常人及缓解期患者相比均有显著性差异。综合治疗可使血浆中Ｅ．Ｐ－选择素水平显著降低；ＰａＯ２与可溶性Ｅ－选择素水平呈负相关（ｒ＝－０．６７，Ｐ＜０．００５）。提示：ＣＤ１１ａ、ＣＤ１１ｂ、ＣＤ４４及Ｅ．Ｐ－选择素粘附分子表达增强参与了ＣＯＰＤ的发病过程；监测血液中可溶性Ｅ－选择素水平可反映病情变化及预后。
Expression of CD11a / CD18, CD11b / CD18 (APAAP) and CD44 (flow cytometry) adhesion molecules on the surface of peripheral blood mononuclear cells (PBMCs) in patients with chronic obstructive pulmonary disease (COPD) P-selectin levels were tested. Results: The expression of CD11a, CD11b and CD44 on the surface of PBMCs in patients with acute exacerbation of COPD was significantly increased, and soluble plasma E P-selectin levels also increased significantly, compared with normal and remission patients were significantly different. Comprehensive treatment can make plasma E P-selectin levels decreased significantly; PaO2 was negatively correlated with soluble E-selectin levels (r = -0.67, P <0.005). Tip: CD11a, CD11b, CD44 and E. The increased expression of P-selectin adhesion molecules is involved in the pathogenesis of COPD. Monitoring the level of soluble E-selectin in the blood can reflect the changes of the disease and prognosis.